Intercept downgraded at RayJay citing potential FDA snub for Ocaliva in NASH (NASDAQ:ICPT)
Candid reporter Intercept Pharma (Nasdaq: ICPT) continued to decline on Wednesday after the Food and Drug Administration (FDA) issued briefing documents prior to the AdCom committee meeting regarding its marketing application for parent…
